Affinity Asset Advisors’s ProQR Therapeutics PRQR Stock Holding History

Affinity Asset Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.98M	Hold	2,454,278	–	–	0.21%	82
2025 Q4	$4.96M	Sell	2,454,278 -1,145,722	-32%	-$2.68M	0.28%	66
2025 Q3	$7.67M	Buy	3,600,000 +100,488	+3%	+$220K	0.67%	42
2025 Q2	$7.14M	Buy	3,499,512 +215,000	+7%	+$350K	0.98%	29
2025 Q1	$4.37M	Buy	3,284,512 +459,512	+16%	+$978K	0.42%	49
2024 Q4	$7.49M	Buy	+2,825,000	New	+$8.97M	1%	29

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Affinity Asset Advisors's PRQR Position: Q1 2026 in Review

Affinity Asset Advisors held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 2,454,278 shares worth $3.98M. The position accounts for 0.21% of the portfolio, ranked #82.

Affinity Asset Advisors first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.67M in Q3 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Affinity Asset Advisors held 2,454,278 shares of ProQR Therapeutics worth $3.98M as of Q1 2026.
Affinity Asset Advisors left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up 0.21% of Affinity Asset Advisors's portfolio in Q1 2026, its #82 holding.
Affinity Asset Advisors first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
Affinity Asset Advisors's ProQR Therapeutics position peaked at $7.67M in Q3 2025.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.